ClinicalTrials.gg
DrugBiological

Mepolizumab clinical trials

Also written Nucala and SB-240563.

studies test it
66
open now
6
in phase 3
27
first study started
2001

How each study uses mepolizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the mepolizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
4 Nov 2015 · NUCALA · BLA 125526 (FDA, Drugs@FDA)
European Union
1 Dec 2015 · Nucala · EMEA/H/C/003860 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Mepolizumab
48
Mepolizumab 100 MG
5
Mepolizumab 300 mg
3
Mepolizumab 100 MG Injection
2

Brand

Nucala
11

Development codes

SB-240563
2

Studies by the year they started

66 studies that test it; most in 2017 (7)

Studies that test mepolizumab, by start year
YearStudies
20011
20042
20052
20061
20071
20082
20091
20112
20125
20132
20145
20153
20163
20177
20181
20193
20203
20216
20224
20237
20243
20251
20261

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
6
Phase 2
16
Phase 3
27
Phase 4
16
No phase
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 32 · Other 34

GlaxoSmithKline (31) · Instituto de Investigación Marqués de Valdecilla (2) · McMaster University (2) · Mayo Clinic (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · St. Paul's Sinus Centre (2) · Centre hospitalier de l'Université de Montréal (CHUM) (1) · Rigshospitalet, Denmark (1)

Often tested with

Tested in the same studies.

Dupilumab (1) · Reslizumab (1) · Omalizumab (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 2 phase 3 studies under way

Mepolizumab is the comparator. A study of two new drugs counts under both.

  • 1Benralizumab · AstraZeneca
  • 1SHR-1703 · Guangdong Hengrui Pharmaceutical Co., Ltd · next primary completion Dec 2028
Reaching primary completion within a year · 3

Studies that test mepolizumab.

Studies

Open first, then newest update. How each study uses mepolizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 66

See all 66 studies that test mepolizumab →

Given beside what is tested · 2 — mepolizumab is usual care or a partner of the new treatment
As the comparator · 6 — what is tested is compared with mepolizumab

Codes

What other systems call mepolizumab · ClinicalTrials.gg INT004376

  • MeSH (NLM) C434107mepolizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 90Z2UF0E52MEPOLIZUMABConfirmed FDA, NLM, Wikidata
  • RxNorm 1720597Confirmed FDA, Wikidata
  • Wikidata Q3306175mepolizumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C157376MepolizumabOne source FDA
  • DrugBank DB06612One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.